{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:34:44Z","timestamp":1787409284133,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI082577"],"award-info":[{"award-number":["R01AI082577"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R15AI082515"],"award-info":[{"award-number":["R15AI082515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science Foundation","award":["MCB-0843603"],"award-info":[{"award-number":["MCB-0843603"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ejmech.2012.07.038","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T04:37:52Z","timestamp":1343709472000},"page":"777-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing"],"prefix":"10.1016","volume":"62","author":[{"given":"Stefan O.","family":"Ochiana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Pandarinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishika","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Ondrechen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Ruben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Pollastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2012.07.038_bib1","first-page":"71","article-title":"Human African trypanosomiasis (sleeping sickness): epidemiological update","volume":"81","year":"2006","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.ejmech.2012.07.038_bib2","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pntd.0000064","article-title":"Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series","volume":"1","author":"Checchi","year":"2007","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejmech.2012.07.038_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.ejmech.2012.07.038_bib4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4155\/fmc.11.92","article-title":"Target repurposing for neglected diseases","volume":"3","author":"Pollastri","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.6775372","article-title":"Polyamine metabolism: a potential therapeutic target in trypanosomes","volume":"210","author":"Bacchi","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.07.038_bib6","doi-asserted-by":"crossref","first-page":"15174","DOI":"10.1021\/bi9915115","article-title":"X-ray structure of ornithine decarboxylase from Trypanosoma brucei:\u2009 the native structure and the structure in complex with \u03b1-difluoromethylornithine","volume":"38","author":"Grishin","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2012.07.038_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0001-706X(93)90089-T","article-title":"Current situation of African trypanosomiasis","volume":"54","author":"Kuzoe","year":"1993","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2012.07.038_bib8","doi-asserted-by":"crossref","DOI":"10.1021\/jm1014617","article-title":"Drug to genome to drug: discovery of new antiplasmodial compounds","author":"Beghyn","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib9","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1021\/jm201148s","article-title":"Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness","volume":"54","author":"Bland","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib10","doi-asserted-by":"crossref","first-page":"e1297","DOI":"10.1371\/journal.pntd.0001297","article-title":"The susceptibility of trypanosomatid pathogens to PI3\/mTOR kinase inhibitors affords a new opportunity for drug repurposing","volume":"5","author":"Diaz-Gonzalez","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejmech.2012.07.038_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2012.07.038_bib12","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1158\/1078-0432.CCR-06-1405","article-title":"Aurora kinases: new targets for cancer therapy","volume":"12","author":"Carvajal","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2012.07.038_bib13","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2174\/138945011798829410","article-title":"Targeting Aurora kinases in cancer treatment","volume":"12","author":"Kelly","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2012.07.038_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2174\/092986709788682227","article-title":"Small molecule aurora kinases inhibitors","volume":"16","author":"Garuti","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1471-2164-6-127","article-title":"Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi","volume":"6","author":"Parsons","year":"2005","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ejmech.2012.07.038_bib16","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1074\/jbc.M511504200","article-title":"An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei","volume":"281","author":"Tu","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib17","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1128\/EC.00129-06","article-title":"Changing roles of aurora-B kinase in two life cycle stages of Trypanosoma brucei","volume":"5","author":"Li","year":"2006","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.ejmech.2012.07.038_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2958.2009.06657.x","article-title":"The cell cycle as a therapeutic target against Trypanosoma brucei: hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms","volume":"72","author":"Jetton","year":"2009","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2012.07.038_bib19","doi-asserted-by":"crossref","first-page":"e1000575","DOI":"10.1371\/journal.ppat.1000575","article-title":"The Aurora kinase in Trypanosoma brucei plays distinctive roles in metaphase-anaphase transition and cytokinetic initiation","volume":"5","author":"Li","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2012.07.038_bib20","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1021\/jm060897w","article-title":"1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles:\u2009 identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile","volume":"49","author":"Fancelli","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib21","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1021\/jm049076m","article-title":"Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition","volume":"48","author":"Fancelli","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.07.038_bib22","first-page":"891","article-title":"Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes","volume":"49","author":"Minowada","year":"1972","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2012.07.038_bib23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-07-0067","article-title":"A\u00a0novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia","volume":"6","author":"Ikezoe","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2012.07.038_bib24","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.bmcl.2008.07.073","article-title":"Discovery of a potent and selective aurora kinase inhibitor","volume":"18","author":"Oslob","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2012.07.038_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/cb100053q","article-title":"Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237","volume":"5","author":"Sloane","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2012.07.038_bib26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/cr9603744","article-title":"The cation-\u03c0 interaction","volume":"97","author":"Ma","year":"1997","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2012.07.038_bib27","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer","volume":"6","author":"Carpinelli","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2012.07.038_bib28","series-title":"Preparation of Pyrrolo[3,4-c]pyrazole Derivatives as IGF-1R Inhibitors","author":"Bandiera","year":"2007"},{"key":"10.1016\/j.ejmech.2012.07.038_bib29","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: a new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2012.07.038_bib30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/prot.22570","article-title":"Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8","volume":"77","author":"Krieger","year":"2009","journal-title":"Proteins: Struct. Funct. Bioinform."},{"key":"10.1016\/j.ejmech.2012.07.038_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.sbi.2006.04.007","article-title":"Protein structure comparison: implications for the nature of \u2018fold space\u2019, and structure and function prediction","volume":"16","author":"Kolodny","year":"2006","journal-title":"Curr. Opin. Struct. Bio."},{"key":"10.1016\/j.ejmech.2012.07.038_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/prot.20251","article-title":"Making optimal use of empirical energy functions: force-field parameterization in crystal space","volume":"57","author":"Krieger","year":"2004","journal-title":"Proteins: Struct. Funct. Bioinform."},{"key":"10.1016\/j.ejmech.2012.07.038_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK \u2013 a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2012.07.038_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2012.07.038_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-2614(01)01229-5","article-title":"OPLS all-atom force field for squaramides and squaric acid","volume":"350","author":"Quinonero","year":"2001","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.ejmech.2012.07.038_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers","volume":"75","author":"Hirumi","year":"1989","journal-title":"J.\u00a0Parasitol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523412004643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523412004643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:39:12Z","timestamp":1588826352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523412004643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":36,"alternative-id":["S0223523412004643"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2012.07.038","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2012.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}